The era of in vivo T cell engineering

Med (N Y). 2022 Feb 11;3(2):85-86. doi: 10.1016/j.medj.2022.01.012.

Abstract

Cell therapy with genetically engineered T cells has revolutionized the treatment of malignant diseases, but its potential use beyond the realms of oncology has been underexplored. In a recent study, Rurik et al.1 built on the technologies underlying mRNA vaccines to transduce T cells in vivo, harnessing them to target cardiac fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Cell Engineering
  • Genetic Engineering
  • Humans
  • Medical Oncology
  • Neoplasms*
  • T-Lymphocytes*